{"transactions":[{"id":1346797,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-02T19:29:28.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":18.94,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001415889-24-028028","document":"form4-12032024_121224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000141588924028028/form4-12032024_121224.xml","form_type":"4"}},{"id":1346796,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-02T19:29:28.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7.06,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-028028","document":"form4-12032024_121224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000141588924028028/form4-12032024_121224.xml","form_type":"4"}},{"id":1346795,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-02T19:29:28.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12367,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.4,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":12367},"source":{"system":"sec-edgar","filing":"0001415889-24-028028","document":"form4-12032024_121224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000141588924028028/form4-12032024_121224.xml","form_type":"4"}},{"id":1346794,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-02T19:29:28.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14428,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":14428},"source":{"system":"sec-edgar","filing":"0001415889-24-028028","document":"form4-12032024_121224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000141588924028028/form4-12032024_121224.xml","form_type":"4"}},{"id":1346793,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-02T19:29:28.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12367,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":12367},"source":{"system":"sec-edgar","filing":"0001415889-24-028028","document":"form4-12032024_121224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000141588924028028/form4-12032024_121224.xml","form_type":"4"}},{"id":1501444,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T16:20:12.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 23, 2024, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders."}],"balance_after":22500,"derivative":{"exercise_price":18.94,"expiration_date":"2034-05-22","underlying":"Voting common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-064612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000095017024064612/ownership.xml","form_type":"4"}},{"id":1875827,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T16:13:30.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 25, 2023, and in any event will become fully vested on the day before the Company's next annual meeting of stockholders."}],"balance_after":12500,"derivative":{"exercise_price":7.06,"expiration_date":"2033-05-24","underlying":"Voting common stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-23-032513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000120919123032513/doc4.xml","form_type":"4"}},{"id":2250794,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T08:29:58.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":12367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 12 equal monthly installments commencing June 24, 2022, and in any event, will become fully vested on the day before the Company's next annual meeting of stockholders."}],"balance_after":12367,"derivative":{"exercise_price":4.4,"expiration_date":"2032-05-23","underlying":"Voting common stock","underlying_shares":12367},"source":{"system":"sec-edgar","filing":"0001209191-22-032735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000120919122032735/doc4.xml","form_type":"4"}},{"id":2442684,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:26:18.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant."}],"balance_after":440000,"derivative":{"exercise_price":13.39,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001209191-22-001824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122001824/doc4.xml","form_type":"4"}},{"id":2502169,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-20T01:58:16.000Z","date":"2021-11-18","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 1/48th of the shares on July 13, 2017, and the remaining shares vested in equal monthly installments from August 13, 2017 and ended on June 13, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The expiration date of this option was erroneously reported as 06/0/1/2022 on the Form 3 filed on May 8, 2019."}],"balance_after":23159,"derivative":{"exercise_price":0.46,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-065993","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121065993/doc4.xml","form_type":"4"}},{"id":2502168,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-20T01:58:16.000Z","date":"2021-11-18","kind":"exercise","acquired":true,"shares":60000,"price":0.46,"value":27600.0,"ownership":{"direct":true},"balance_after":109895,"source":{"system":"sec-edgar","filing":"0001209191-21-065993","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121065993/doc4.xml","form_type":"4"}},{"id":2715808,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:51:32.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":183,"price":36.73,"value":6721.59,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":978774,"source":{"system":"sec-edgar","filing":"0001209191-21-032078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121032078/doc4.xml","form_type":"4"}},{"id":2715807,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:51:32.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":6315,"price":35.81,"value":226140.15,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.44 to $36.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":978957,"source":{"system":"sec-edgar","filing":"0001209191-21-032078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121032078/doc4.xml","form_type":"4"}},{"id":2715806,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:51:32.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":9918,"price":34.89,"value":346039.02,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.41 to $35.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":985272,"source":{"system":"sec-edgar","filing":"0001209191-21-032078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121032078/doc4.xml","form_type":"4"}},{"id":2715805,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-12T20:51:32.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":13584,"price":33.75,"value":458460.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020 and amended on December 18, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.41 to $34.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":995190,"source":{"system":"sec-edgar","filing":"0001209191-21-032078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121032078/doc4.xml","form_type":"4"}},{"id":2774111,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-23T23:06:47.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":400,"price":36.6,"value":14640.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1008774,"source":{"system":"sec-edgar","filing":"0001209191-21-022682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121022682/doc4.xml","form_type":"4"}},{"id":2774110,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-23T23:06:47.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":300,"price":36.58,"value":10974.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1009174,"source":{"system":"sec-edgar","filing":"0001209191-21-022682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121022682/doc4.xml","form_type":"4"}},{"id":2774109,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-23T23:06:47.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":18089,"price":35.85,"value":648490.65,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.42 to $36.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1009474,"source":{"system":"sec-edgar","filing":"0001209191-21-022682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121022682/doc4.xml","form_type":"4"}},{"id":2774108,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-23T23:06:47.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":11211,"price":35.1,"value":393506.1,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.41 to $35.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1027563,"source":{"system":"sec-edgar","filing":"0001209191-21-022682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121022682/doc4.xml","form_type":"4"}},{"id":2794003,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-11T20:36:15.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":14428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option vest and become exercisable in 14 equal monthly installments commencing March 28, 2021."}],"balance_after":14428,"derivative":{"exercise_price":16,"expiration_date":"2031-03-10","underlying":"Voting Common Stock","underlying_shares":14428},"source":{"system":"sec-edgar","filing":"0001209191-21-019992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000120919121019992/doc4.xml","form_type":"4"}},{"id":2794002,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-11T20:36:15.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":12367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 36 equal monthly installments commencing March 28, 2021."}],"balance_after":12367,"derivative":{"exercise_price":16,"expiration_date":"2031-03-10","underlying":"Voting Common Stock","underlying_shares":12367},"source":{"system":"sec-edgar","filing":"0001209191-21-019992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770783/000120919121019992/doc4.xml","form_type":"4"}},{"id":2880657,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":600,"price":45.73,"value":27438.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $45.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1038774,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880656,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":8032,"price":45,"value":361440.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.54 to $45.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1039374,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880655,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":1900,"price":44.22,"value":84018.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.53 to $44.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1047406,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880654,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":1512,"price":43.1,"value":65167.2,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.50 to $43.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1049306,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880653,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":3100,"price":41.91,"value":129921.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.46 to $42.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1050818,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880652,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":2000,"price":40.84,"value":81680.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.42 to $41.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1053918,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880651,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":856,"price":39.82,"value":34085.92,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $40.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1055918,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880650,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":1600,"price":38.64,"value":61824.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $39.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1056774,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880649,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":400,"price":37.39,"value":14956.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1058374,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880648,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":5071,"price":36.75,"value":186359.25,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $36.53 to $36.94, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1058774,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880647,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":14929,"price":36.02,"value":537742.58,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $35.52 to $36.49, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1063845,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880646,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":371,"price":39.23,"value":14554.33,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1078774,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880645,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":100,"price":38.28,"value":3828.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1079145,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880644,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":4283,"price":37.68,"value":161383.44,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $37.25 to $38.25, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1079245,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880643,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":7460,"price":36.56,"value":272737.6,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $36.21 to $37.20, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1083528,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880642,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":3100,"price":35.59,"value":110329.0,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $35.165 to $36.145, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1090988,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2880641,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-04T00:45:08.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":4686,"price":34.6,"value":162135.6,"ownership":{"direct":false,"nature":"By the Zachary and Casey Lynch Living Trust dated February 24, 2009"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $34.15 to $35.14, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Casey C. Lynch is a trustee of the Zachary and Casey Lynch Living Trust dated February 24, 2009, and shares voting and dispositive power with one other trustee with respect to the shares held of record by the Zachary and Casey Lynch Living Trust dated February 24, 2009."}],"balance_after":1094088,"source":{"system":"sec-edgar","filing":"0001209191-21-007540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121007540/doc4.xml","form_type":"4"}},{"id":2943978,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-16T00:13:27.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share."}],"balance_after":175000,"derivative":{"exercise_price":29.6,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-20-063609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919120063609/doc4.xml","form_type":"4"}},{"id":2943977,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-16T00:13:27.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date."}],"balance_after":175000,"derivative":{"exercise_price":29.6,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-20-063609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919120063609/doc4.xml","form_type":"4"}},{"id":3281515,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":85537,"kind":"person","name":"Lynch Casey","position":1,"cik":"0001770783","reported_name":"Lynch Casey","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-10T23:08:57.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest and become exercisable monthly over four years."}],"balance_after":175000,"derivative":{"exercise_price":54.85,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-20-008064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919120008064/doc4.xml","form_type":"4"}}]}